Skip to main content

Table 1 Demographic characteristics of the cycles

From: Analysis of euploidy rates in preimplantation genetic testing for aneuploidy cycles with progestin-primed versus GnRH agonist/antagonist protocol

Variables

Ovarian stimulation protocol

p value

PPOS

GnRH agonist

GnRH antagonist

No. of PGT-A cycles

146

160

302

 

Female age (years)

38(33–41)

35(32–39)

37(33–40)

0.001a,c

BMI (kg/m2)

22.05(20.3–24.2)

21.6(20.3–23.4)

21.2(19.6–23.2)

0.010b

Primary infertility (%)*

22.6%(33/146)

11.25%(18/160)

21.52%(65/302)

0.013a,c

Secondary infertility (%)*

77.4%(113/146)

88.75%(142/160)

78.48%(237/302)

0.013c

Infertility duration (years)

1.5(1–3.75)

2(1–4)

2(1–3)

0.896

AMH

2.49(1.12–5.59)

3.33(2.33–4.76)

2.7(1.45–4.86)

0.06

bFSH

7.59(5.6–9)

6.3(4.98–7.28)

7.11(5.97–8.52)

0.000a,c

AFC

12(6–20)

14(10–19)

11(6–17)

0.138

Indication of PGT-A (%)*

0.001

 Advanced maternal age

26.03%(38/146)

14.38%(23/160)

24.83%(75/302)

 

 Recurrent miscarriage

19.18%(28/146)

44.38%(71/160)

32.78%(99/302)

 

 Repeated implantation failure

25.34%(37/146)

19.38%(31/160)

16.89%(51/302)

 

 Mixed

29.45%(43/146)

21.88%(35/160)

25.50%(77/302)

 
  1. aPPOS vs. GnRH agonist, p < 0.05
  2. bPPOS vs. GnRH antagonist, p < 0.05
  3. cGnRH agonist vs. GnRH antagonist, p < 0.05
  4. *P-value is considered to be significant when < 0.016 [Bonferroni correction (0.05/3)]